Diaceutics and IQM Redefine HCP Marketing with Real-Time, AI-Powered Diagnostic Audiences

We are delighted to announce our latest partnership with IQM Advertising Corporation. As leaders in AI-driven diagnostic and genomic data for smarter HCP marketing, we're teaming up with this media buying platform.

This exciting new collaboration is set to empower advertisers working in the most regulated verticals. What it means is that they'll have the tools to enhance their data to make better ad-buying decisions. Together, we are unlocking a first-of-its-kind capability. Real-time activation of diagnostic-informed HCP audiences across IQM’s intelligent media infrastructure.

Our partnership will challenge the status quo of healthcare marketing. It will usurp outdated claims data, fragmented insights, and rigid compliance models. By fusing our clinically validated diagnostic signals with IQM’s proprietary, AI-powered audience engine, we are delivering a new frontier in precision HCP marketing. That is: faster, smarter, and built for pharmaceutical-grade compliance.

“IQM’s infrastructure is built from the ground up to solve the toughest targeting and compliance challenges in healthcare. When you layer in real-time diagnostic triggers, signals grounded in patient testing and treatment decisions, you move from broad targeting to precision at the point of care. That’s where behavior changes, and that’s where therapy adoption accelerates.”

– Scott Phillips, VP, Real World Data at Diaceutics

The integration makes our extensive catalog of pre-built, diagnostically driven audience segments available within IQM’s platform. These include chronic conditions such as:

• Diabetes
• Cardiovascular disease
• Biomarker-specific oncology pathways (e.g., EGFR, HER2, PD-L1)
• And even hard-to-reach rare disease populations

These advanced segments allow HCP marketing campaigns to trigger in real-time. Our data is based on diagnostic or lab events rather than months-old claims data. Notably, marketers will be able to engage HCPs in the moment of clinical relevance. That is, when treatment decisions are being made. From this, they can identify hidden treaters actively managing patients invisible to traditional targeting models.

“The speed from claims data to activation is one of the strongest indicators of intent. Now that we have access to lab data, we can identify when a physician orders a lab for a patient. This allows us to engage the HCP proactively, even before a diagnosis is made or a prescription is written.”

– Tony Sherry, GM Healthcare Lead at IQM.

Ultimately, this integration optimizes campaigns with AI-driven precision, without sacrificing regulatory rigor. This is a first-ever for the industry at large. Together, we are turning real-time diagnostic insights into actionable intelligence. Driving HCP marketing that moves as fast as medicine itself.

“IQM was built to solve the hardest problems in healthcare advertising – precision, compliance, and speed. Partnering with Diaceutics takes that mission even further. We can now combine real-time clinical intelligence with our robust infrastructure. This will give pharma and healthcare marketers a first-ever ability to act on clinically dynamic data at programmatic speed with pharmaceutical-grade compliance.”

– Kris Qiu, CEO of IQM.

Our partnership underscores that the next era of healthcare marketing is here. And that era will be driven by intelligence, adaptability, and responsibly precise data.

About Diaceutics

Diaceutics exists to ensure every patient gets the right test and the right therapy at the right time. For over 20 years, we’ve partnered with the world’s leading pharma and biotech companies to close the gap between diagnostics and therapy adoption. Our platform and solutions are built on one of the most comprehensive real-world diagnostic data sets in the industry, enabling our partners to commercialize with precision, at scale.

About IQM

IQM is a global media buying platform that empowers specialty advertisers, such as HCP marketing. These include political, healthcare, and other specialty sectors in highly regulated verticals. It enables them to use and enhance their data to make better ad buying decisions.

Their platform enables advertisers to construct precise audience segments. They align seamlessly with their desired target audience base. This is through a combination of their own data, top-tier third-party data sources, and IQM’s proprietary AI-driven audience intelligence engine. What can clients expect? This leads to more accurate forecasting, budgeting, and targeting. It also delivers campaigns that perform better across screens and formats.

IQM has been honored with numerous awards. These include: Best Demand-Side Platform award at the 2025 MarTech Breakthrough Awards and the Best Demand-Side Technology award at the 2025 AdExchanger Awards. These accolades highlight its leadership in innovation and excellence in programmatic advertising.

For more information, visit www.iqm.com